Markets:

Overview

News

Currencies

International

Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.608 -0.242 (-4.99%)

Streaming Delayed Price Updated: 12:35 PM EST, Jan 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 06, 2023

Via Benzinga

Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023

March 31, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results

March 29, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients ↗

March 21, 2023

Via Benzinga

There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study

March 29, 2023

There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study

Via News Direct

There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study

March 29, 2023

By David Willey, Benzinga

Via TheNewswire.com

There Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study ↗

March 28, 2023

Coya Therapeutics (NASDAQ: COYA) has just reported proof of concept data from its trial for COYA 302, a new combination drug for treating amyotrophic lateral sclerosis (ALS).

Via Benzinga

Coya Therapeutics: This BioPharma Company Has Some Big News To Share ↗

March 27, 2023

Howard Burman, Ph.D, CEO & Chairman of Coya Therapeutics Inc (NASDAQ: COYA), was a guest on Benzinga’s All Access.

Via Benzinga

Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

March 27, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

March 23, 2023

By David Willey, Benzinga

Via TheNewswire.com

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

March 23, 2023

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development

Via News Direct

Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET

March 23, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study

March 22, 2023

By David Willey, Benzinga

Via TheNewswire.com

Topics Death

Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study

March 22, 2023

Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study

Via News Direct

Topics Death

Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development ↗

March 22, 2023

Houston-based Coya Therapeutics (NASDAQ: COYA) has entered into a partnership with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a world-leading pharmaceutical company based in India.

Via Benzinga

Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study ↗

March 21, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to...

Via Benzinga

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

March 21, 2023

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

Via News Direct

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

March 21, 2023

By Kenneth Adams, Benzinga

Via TheNewswire.com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 21, 2023

Via Benzinga

Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET

March 21, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)

March 21, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302 ↗

March 20, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited.

Via Benzinga

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

March 20, 2023

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET

March 09, 2023

From Coya Therapeutics, Inc.

Via Business Wire

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?

March 06, 2023

By David Willey, Benzinga

Via TheNewswire.com

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?

March 06, 2023

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?

Via News Direct

This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier? ↗

March 03, 2023

Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field.

Via Benzinga

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

February 28, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary...

Via TheNewswire.com

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

February 28, 2023

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas

Via News Direct

Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas ↗

February 27, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.